In a recent small-scale study, rectal cancer patients who took a new type of drug showed 100% success in eradicating their disease. All patients had no recurrence, no significant side effects, and no sign of cancer. The drug, Dostarlimab, was administered with no side effects and no surgery. In this study, patients were diagnosed with rectal cancer.
Dostarlimab Cures Rectal Cancer
In a small clinical trial conducted by Dr. Luis A. Diaz of the Memorial Sloan Kettering Cancer Center, a monoclonal antibody known as dostarlimab cured rectal cancer in every patient. The drug, which was administered every three weeks for six months, eliminated cancer from every patient. The researchers performed PET scans, biopsies, and endoscopic tests, and found that the tumors were completely cured in all patients.
The study involved 12 people with rectal cancer. Each patient received the experimental drug called dostarlimab. Researchers also found that none of the patients had significant side effects. The results of the trial were published in the New England Journal of Medicine. The lead author of the study, Dr. Luis Diaz, is a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City.
The drug was given to all the patients in a 12-person clinical trial. In all, the drug cured rectal cancer in every patient. The drug’s effectiveness was determined by the results of an external expert who noted that the results were compelling but were not a 100% cure. Nevertheless, the researchers say dostarlimab has the potential to cure rectal cancer in every patient, despite its relatively small sample size.
No Significant Side Effects Found
The new drug called an immunotherapy checkpoint inhibitor, did not cause significant side effects in the study. It was administered to patients with rectal adenocarcinoma. While these drugs have been available for melanoma for some time, they have only recently been included in routine colorectal cancer treatment. The drugs were also well tolerated by the patients, and the trial found that the new drug caused no significant side effects in every patient.
Sascha Roth, a 38-year-old woman from Germany, was part of the drug trial. When she noticed her rectal bleeding in early 2019, she was still feeling fine. However, when her gastroenterologist examined the tumor, he found that it was a tumor and it was cancer. Roth decided to be part of the drug trial and planned to relocate to New York for chemotherapy and radiation. After the treatment, she had her ovaries repositioned under her ribs to preserve her fertility.
No Regrowth Of Tumors
Dostarlimab, a drug being tested for treating advanced cancer, is proving to be a revolutionary new drug. It was shown to completely cure all patients in a clinical trial. The trial lasted only six months. After that, all participants were free of tumors. The drug is a laboratory-produced molecule that functions as a substitute antibody in the human body.